Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amyloid beta (Aβ) peptide aggregates are assemblies of Aβ peptides, short fragments derived from the amyloid precursor protein (APP). These aggregates are central to Alzheimer’s disease pathology, accumulating as extracellular plaques and contributing to neurodegeneration. They exist in various forms, including oligomers, protofibrils, and fibrils, with oligomers being particularly neurotoxic. Therapeutic strategies focus on inhibiting aggregation, promoting clearance, and blocking toxic interactions with neuronal receptors.
Inhibition of aggregation; promotion of clearance/degradation; blocking toxic interactions with neuronal receptors; reduction of Aβ production.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Amyloid beta peptide aggregate.